{"product_id":"jnj-business-model-canvas","title":"Johnson \u0026 Johnson (JNJ): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas gives you a practical, research-based view of Company Name's business model, showing how oncology and immunology R\u0026amp;D, MedTech launches, AI-enabled operations, and a global manufacturing network work together to create value. You'll see how the company serves hospitals, physicians, payers, health systems, and cancer centers through direct sales, clinical education, and regulatory pathways, while generating revenue from innovative medicine and device sales, new launches, and acquired franchises. It also highlights key partnerships, major cost drivers, and the strategic resources behind its market position.\u003c\/p\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson uses partnerships to turn \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e of 2024 R\u0026amp;D spending into products that still need 510(k), PMA, De Novo, FDA, EMA, and reimbursement decisions. Its \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 net sales and \u003cstrong\u003e19.4%\u003c\/strong\u003e R\u0026amp;D-to-sales ratio show why external science, devices, and clinical channels matter.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003ePublic financial terms\u003c\/th\u003e\n\u003cth\u003eBusiness role\u003c\/th\u003e\n\u003cth\u003eFinancial relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinMaxMedical\u003c\/td\u003e\n\u003ctd\u003eGemtrack tracking tech\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003ctd\u003eSurgical tracking and navigation\u003c\/td\u003e\n\u003ctd\u003eSupports device differentiation and integration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtraverse Medical\u003c\/td\u003e\n\u003ctd\u003eCardiac access tools\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003ctd\u003eStructural heart access\u003c\/td\u003e\n\u003ctd\u003eExpands procedure capability and workflow control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalda Therapeutics\u003c\/td\u003e\n\u003ctd\u003eOncology pipeline\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003ctd\u003eEarly-stage cancer science\u003c\/td\u003e\n\u003ctd\u003eBroadens the pipeline without full internal buildout\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunityBio\u003c\/td\u003e\n\u003ctd\u003eBladder cancer collaboration\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003ctd\u003eOncology development and clinical execution\u003c\/td\u003e\n\u003ctd\u003eShares clinical and regulatory risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators and health systems\u003c\/td\u003e\n\u003ctd\u003eApprovals and adoption\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eFDA, EMA, hospitals, payers\u003c\/td\u003e\n\u003ctd\u003eTurns R\u0026amp;D spend into revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eMinMaxMedical and Atraverse Medical sit on the MedTech side of the model. These partnerships give Johnson \u0026amp; Johnson access to specialized tracking and cardiac access technology without starting from zero. That matters because device businesses are built on engineering cycles, verification, clinical adoption, and surgeon workflow. A tool that fits the procedure better can matter as much as a drug dose, because hospitals buy products that save time, reduce risk, and fit existing operating-room routines.\u003c\/p\u003e\n\n\u003cp\u003eHalda Therapeutics and ImmunityBio sit on the oncology side. The partnership logic is the same: external biology, internal scale. Oncology development is expensive because it needs target discovery, biomarker work, trial design, and long follow-up periods. Partnerships can shift some of that cost and risk off Johnson \u0026amp; Johnson's balance sheet while keeping access to the pipeline. In valuation terms, that can improve the value of future cash flows in today's dollars if development time comes down.\u003c\/p\u003e\n\n\u003cp\u003eRegulators and health systems are the most important non-financial partners in this model. In the United States, device programs can move through \u003cstrong\u003e510(k)\u003c\/strong\u003e, \u003cstrong\u003ePMA\u003c\/strong\u003e, or \u003cstrong\u003eDe Novo\u003c\/strong\u003e pathways. Drug programs depend on FDA review, and European access depends on EMA and CE-mark-related routes. Hospitals, academic centers, and integrated delivery networks then provide the case volume, outcome data, and reimbursement evidence needed to convert approval into sales. Without those partners, a launch stays a filing, not a product line.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e2024 net sales: \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D expense: \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D as a share of sales: \u003cstrong\u003e19.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCore operating segments: \u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDevice approval pathways: 510(k), PMA, De Novo\u003c\/li\u003e\n\u003cli\u003eMarket-access gatekeepers: FDA, EMA, hospitals, payers\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson key activities are built around \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e of 2024 R\u0026amp;D spending, \u003cstrong\u003e$13.1 billion\u003c\/strong\u003e for Shockwave Medical, \u003cstrong\u003e$16.6 billion\u003c\/strong\u003e for Abiomed, and a U.S. investment plan of more than \u003cstrong\u003e$55 billion\u003c\/strong\u003e over \u003cstrong\u003e4 years\u003c\/strong\u003e. In 2024, the company generated \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in worldwide sales, and R\u0026amp;D alone represented \u003cstrong\u003e19.4%\u003c\/strong\u003e of that base.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey activity\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eBusiness-model effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology and immunology R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$17.2 billion\u003c\/strong\u003e in 2024; \u003cstrong\u003e19.4%\u003c\/strong\u003e of \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e sales\u003c\/td\u003e\n \u003ctd\u003eFunds discovery, Phase 1 to Phase 3 trials, and label expansion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech device development and launches\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$13.1 billion\u003c\/strong\u003e Shockwave Medical; \u003cstrong\u003e$16.6 billion\u003c\/strong\u003e Abiomed; \u003cstrong\u003e$29.7 billion\u003c\/strong\u003e combined\u003c\/td\u003e\n \u003ctd\u003eBuilds cardiovascular and interventional device breadth\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials and regulatory filings\u003c\/td\u003e\n\u003ctd\u003eCARVYKTI approval on \u003cstrong\u003eApril 5, 2024\u003c\/strong\u003e; R\u0026amp;D budget \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eTurns trial data into approvals and new indications\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A integration and spinoff execution\u003c\/td\u003e\n \u003ctd\u003eKenvue separation on \u003cstrong\u003eAugust 23, 2023\u003c\/strong\u003e; \u003cstrong\u003e$29.7 billion\u003c\/strong\u003e combined MedTech deals\u003c\/td\u003e\n \u003ctd\u003eFocuses capital on pharma and MedTech\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-enabled manufacturing and operations\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e$55 billion\u003c\/strong\u003e U.S. investment over \u003cstrong\u003e4 years\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eSupports automation, quality systems, and supply resilience\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOncology and immunology R\u0026amp;D: Johnson \u0026amp; Johnson spent \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e on R\u0026amp;D in 2024, which was \u003cstrong\u003e19.4%\u003c\/strong\u003e of \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in worldwide sales. That is nearly \u003cstrong\u003e$1\u003c\/strong\u003e in every \u003cstrong\u003e$5\u003c\/strong\u003e of sales going back into science. In practical terms, this budget pays for discovery work, biomarker studies, patient enrollment, safety monitoring, and the statistical analysis needed to support approvals and new label expansions.\u003c\/p\u003e\n\n\u003cp\u003eMedTech device development and launches: the company paid \u003cstrong\u003e$13.1 billion\u003c\/strong\u003e for Shockwave Medical in 2024 and \u003cstrong\u003e$16.6 billion\u003c\/strong\u003e for Abiomed in 2022, for a combined \u003cstrong\u003e$29.7 billion\u003c\/strong\u003e. Against \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e of 2024 sales, that is \u003cstrong\u003e33.4%\u003c\/strong\u003e. This shows that device innovation is not just internal R\u0026amp;D; Johnson \u0026amp; Johnson also buys platform technologies and then spends on integration, validation, training, and launch execution.\u003c\/p\u003e\n\n\u003cp\u003eClinical trials and regulatory filings: on \u003cstrong\u003eApril 5, 2024\u003c\/strong\u003e, CARVYKTI won earlier-line U.S. approval in multiple myeloma. That kind of event depends on the same \u003cstrong\u003e$17.2 billion\u003c\/strong\u003e R\u0026amp;D engine because trial design, site management, safety data, chemistry, manufacturing, and controls, and filing work all sit inside the development budget. For a company like Johnson \u0026amp; Johnson, approval speed matters because every extra indication can extend a product life cycle by years.\u003c\/p\u003e\n\n\u003cp\u003eM\u0026amp;A integration and spinoff execution: Johnson \u0026amp; Johnson completed the separation of Kenvue on \u003cstrong\u003eAugust 23, 2023\u003c\/strong\u003e, which removed the consumer health business from the operating model. Since then, major MedTech deal activity has included \u003cstrong\u003e$13.1 billion\u003c\/strong\u003e for Shockwave Medical and \u003cstrong\u003e$16.6 billion\u003c\/strong\u003e for Abiomed, or \u003cstrong\u003e$29.7 billion\u003c\/strong\u003e combined. Integration work matters because a deal only creates value if the company can move products, people, systems, and regulatory files onto one operating platform.\u003c\/p\u003e\n\n\u003cp\u003eAI-enabled manufacturing and operations: Johnson \u0026amp; Johnson announced a U.S. investment plan of more than \u003cstrong\u003e$55 billion\u003c\/strong\u003e over \u003cstrong\u003e4 years\u003c\/strong\u003e. In operational terms, that scale gives the company room to fund automation, digital quality control, predictive maintenance, planning tools, and supply chain redundancy across pharma and MedTech plants. With \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 sales, operations have to be strong enough to support both regulated drug production and high-volume device manufacturing.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e 2024 worldwide sales\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$17.2 billion\u003c\/strong\u003e 2024 R\u0026amp;D expense\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e19.4%\u003c\/strong\u003e R\u0026amp;D as a share of sales\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$13.1 billion\u003c\/strong\u003e Shockwave Medical acquisition\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$16.6 billion\u003c\/strong\u003e Abiomed acquisition\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$29.7 billion\u003c\/strong\u003e combined MedTech deal value\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eApril 5, 2024\u003c\/strong\u003e CARVYKTI earlier-line U.S. approval\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eAugust 23, 2023\u003c\/strong\u003e Kenvue separation completion\u003c\/li\u003e\n \u003cli\u003eMore than \u003cstrong\u003e$55 billion\u003c\/strong\u003e U.S. investment over \u003cstrong\u003e4 years\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e total 2024 net sales, with \u003cstrong\u003e$57.1B\u003c\/strong\u003e from Innovative Medicine and \u003cstrong\u003e$31.7B\u003c\/strong\u003e from MedTech.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey resource\u003c\/td\u003e\n\u003ctd\u003eNumbers\u003c\/td\u003e\n\u003ctd\u003eDate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInnovative Medicine portfolio\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$57.1B\u003c\/strong\u003e sales\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech franchises and robotic platforms\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$31.7B\u003c\/strong\u003e sales\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and marketable securities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$13.1B\u003c\/strong\u003e Shockwave Medical; \u003cstrong\u003e$14.6B\u003c\/strong\u003e Intra-Cellular Therapies; \u003cstrong\u003e$27.7B\u003c\/strong\u003e combined\u003c\/td\u003e\n\u003ctd\u003e2024-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal manufacturing network\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60\u003c\/strong\u003e countries; \u003cstrong\u003e175\u003c\/strong\u003e countries; \u003cstrong\u003e138,100\u003c\/strong\u003e employees\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents, data, and AI tools\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$17.2B\u003c\/strong\u003e R\u0026amp;D expense; \u003cstrong\u003e19.4%\u003c\/strong\u003e of sales\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e64.3%\u003c\/strong\u003e of 2024 net sales came from Innovative Medicine and \u003cstrong\u003e35.7%\u003c\/strong\u003e came from MedTech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$17.2B\u003c\/strong\u003e divided by \u003cstrong\u003e$88.8B\u003c\/strong\u003e equals \u003cstrong\u003e19.4%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$57.1B\u003c\/strong\u003e Innovative Medicine sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$31.7B\u003c\/strong\u003e MedTech sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$17.2B\u003c\/strong\u003e R\u0026amp;D expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e19.4%\u003c\/strong\u003e R\u0026amp;D as a share of sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e60\u003c\/strong\u003e countries with operations\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e175\u003c\/strong\u003e countries with product sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e138,100\u003c\/strong\u003e employees\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$13.1B\u003c\/strong\u003e Shockwave Medical transaction value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$14.6B\u003c\/strong\u003e Intra-Cellular Therapies transaction value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$27.7B\u003c\/strong\u003e combined transaction value\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2024\u003c\/strong\u003e net sales were \u003cstrong\u003e$88.8B\u003c\/strong\u003e, with \u003cstrong\u003e2\u003c\/strong\u003e segments producing \u003cstrong\u003e$57.0B\u003c\/strong\u003e in Innovative Medicine and \u003cstrong\u003e$31.8B\u003c\/strong\u003e in MedTech.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eValue proposition\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003eCompany basis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-science medicines and devices\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$88.8B\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e; \u003cstrong\u003e$57.0B\u003c\/strong\u003e; \u003cstrong\u003e$31.8B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024 net sales; Innovative Medicine; MedTech\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlockbuster therapies in oncology and immunology\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.7B\u003c\/strong\u003e; \u003cstrong\u003e$10.4B\u003c\/strong\u003e; \u003cstrong\u003e$3.7B\u003c\/strong\u003e; \u003cstrong\u003e$3.0B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDarzalex; Stelara; Tremfya; Erleada\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced surgical and cardiovascular innovation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$31.8B\u003c\/strong\u003e; \u003cstrong\u003e$16.6B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMedTech sales; Abiomed acquisition value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster development via AI\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 research and development expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReliable U.S.-based supply resilience\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$55B\u003c\/strong\u003e; \u003cstrong\u003e4\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eU.S. manufacturing, R\u0026amp;D, and technology investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-science medicines and devices\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$57.0B\u003c\/strong\u003e Innovative Medicine sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$31.8B\u003c\/strong\u003e MedTech sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$88.8B\u003c\/strong\u003e total net sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBlockbuster therapies in oncology and immunology\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.7B\u003c\/strong\u003e Darzalex\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.4B\u003c\/strong\u003e Stelara\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.7B\u003c\/strong\u003e Tremfya\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.0B\u003c\/strong\u003e Erleada\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdvanced surgical and cardiovascular innovation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$31.8B\u003c\/strong\u003e MedTech sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$16.6B\u003c\/strong\u003e Abiomed acquisition value\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFaster development via AI\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$17.2B\u003c\/strong\u003e 2024 research and development expense\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eReliable U.S.-based supply resilience\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$55B\u003c\/strong\u003e U.S. manufacturing, R\u0026amp;D, and technology investment\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e years\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson's customer relationships are built around recurring clinical use, payer access, and account-level support. The company reported \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 net sales and operates through \u003cstrong\u003e2\u003c\/strong\u003e segments, so the relationship model is designed for large institutional buyers rather than one-time transactions.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer relationship area\u003c\/th\u003e\n\u003cth\u003eReal-life numbers or amounts\u003c\/th\u003e\n\u003cth\u003eCustomer relationship signal\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales teams with AI copilots\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e segments; \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 net sales\u003c\/td\u003e\n\u003ctd\u003eHigh-touch account coverage at large scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term hospital and physician support\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major institutional buyer groups\u003c\/td\u003e\n\u003ctd\u003eRecurring service, replenishment, and support cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvidence-led product adoption\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e drugs in the first U.S. Medicare negotiation cycle; \u003cstrong\u003e15\u003c\/strong\u003e drugs in the second cycle\u003c\/td\u003e\n\u003ctd\u003eAdoption depends on evidence, coverage, and comparative value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer and government pricing negotiations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2026\u003c\/strong\u003e first effective year for negotiated prices\u003c\/td\u003e\n\u003ctd\u003ePricing follows multi-year regulatory timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical education and training\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e segments\u003c\/td\u003e\n\u003ctd\u003eTraining has to support medicines and devices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect sales teams with AI copilots.\u003c\/strong\u003e Johnson \u0026amp; Johnson does not separately disclose AI copilot spending. The public scale marker is \u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 net sales across \u003cstrong\u003e2\u003c\/strong\u003e segments, which points to a field model built for hospitals, physicians, and procurement teams that need repeated contact and account management.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-term hospital and physician support.\u003c\/strong\u003e The relationship is not a single-sale model. It depends on repeated purchasing, installation, service, and use in clinical settings, so retention matters as much as initial adoption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEvidence-led product adoption.\u003c\/strong\u003e U.S. payer behavior shows why evidence matters. The first Medicare drug negotiation cycle selected \u003cstrong\u003e10\u003c\/strong\u003e drugs, the second cycle selected \u003cstrong\u003e15\u003c\/strong\u003e drugs, and the first negotiated prices take effect in \u003cstrong\u003e2026\u003c\/strong\u003e. That makes coverage, comparative data, and clinical proof central to adoption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayer and government pricing negotiations.\u003c\/strong\u003e Price is managed through multi-year processes, not one-off discounts. A negotiated price that begins in \u003cstrong\u003e2026\u003c\/strong\u003e means the relationship with government and payer customers has to be maintained well before launch, during launch, and after market entry.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical education and training.\u003c\/strong\u003e In a \u003cstrong\u003e2\u003c\/strong\u003e-segment company, training has to cover both pharmaceutical and medical technology buyers. That means clinician education, operating-room support, and product-use training are part of customer retention, not just marketing spend.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$88.8 billion\u003c\/strong\u003e in 2024 net sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e drugs in the first U.S. Medicare negotiation cycle\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e drugs in the second U.S. Medicare negotiation cycle\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2026\u003c\/strong\u003e first effective year for negotiated prices\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eJohnson \u0026amp; Johnson reported $85.2 billion in 2023 sales.\u003c\/strong\u003e \u003cstrong\u003e$55.1 billion\u003c\/strong\u003e came from Innovative Medicine and \u003cstrong\u003e$30.1 billion\u003c\/strong\u003e came from MedTech, so the company's channels are built around hospital purchasing, specialist access, surgical workflows, and regulated launches rather than mass retail.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospital procurement systems\u003c\/strong\u003e are the main route for MedTech volume. These channels run through hospital systems, group purchasing organizations, and integrated delivery networks, where buying decisions depend on contract terms, procedure volume, and value analysis committees. For devices and procedure tools, the channel is less about shelf space and more about being approved inside the hospital's purchasing process. That matters because one contract can influence recurring demand across operating rooms, outpatient surgery centers, and inpatient units. In revenue terms, this channel sits behind the \u003cstrong\u003e$30.1 billion\u003c\/strong\u003e MedTech business, which was \u003cstrong\u003e35.3%\u003c\/strong\u003e of Johnson \u0026amp; Johnson's \u003cstrong\u003e$85.2 billion\u003c\/strong\u003e total sales in 2023.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eReal-life numeric anchor\u003c\/th\u003e\n\u003cth\u003eChannel effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital procurement systems\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSystem-level purchasing drives MedTech access and repeat orders.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician and specialist sales force\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSpecialist prescribing and formulary placement drive Innovative Medicine access.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany total sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$85.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows the scale of channel execution across both segments.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales mix\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e64.7%\u003c\/strong\u003e Innovative Medicine, \u003cstrong\u003e35.3%\u003c\/strong\u003e MedTech\u003c\/td\u003e\n\u003ctd\u003eShows where the company's channel weight sits.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhysician and specialist sales force\u003c\/strong\u003e is the core channel for Innovative Medicine. The company sells through field teams that reach oncologists, dermatologists, rheumatologists, cardiologists, and other specialists who decide whether a medicine gets used and how fast it scales. For this channel, access depends on prescribing behavior, payer coverage, and formulary placement, the approved drug list used by a health system. This channel matters because medicines usually do not scale just on approval; they scale when specialists adopt them and payers agree to reimburse them. The \u003cstrong\u003e$55.1 billion\u003c\/strong\u003e Innovative Medicine segment accounted for \u003cstrong\u003e64.7%\u003c\/strong\u003e of Johnson \u0026amp; Johnson's 2023 sales, which shows how important specialist access is to the business model.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSpecialist access is tied to prescribing, not retail foot traffic.\u003c\/li\u003e\n\u003cli\u003eFormulary placement affects whether volume can grow inside a health system.\u003c\/li\u003e\n\u003cli\u003ePayer coverage affects how fast prescriptions convert into revenue.\u003c\/li\u003e\n\u003cli\u003eMedical science liaisons and field teams support clinical adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSurgical and digital platforms\u003c\/strong\u003e connect the MedTech business to the operating room and procedure center. These channels include surgical equipment, instrumentation, visualization, workflow software, and connected platforms that are adopted by surgeons and hospital administrators together. The buying process is usually longer than a simple product sale because hospitals look at training time, service support, capital budgets, and procedure efficiency. In channel terms, this is a procedure-based model: adoption happens when the product becomes part of the clinical workflow. That matters because once a platform is embedded in surgery, switching costs rise and repeat use becomes more likely. Johnson \u0026amp; Johnson's two operating segments, \u003cstrong\u003eInnovative Medicine\u003c\/strong\u003e and \u003cstrong\u003eMedTech\u003c\/strong\u003e, show how the company separates medicine access from procedure-based access.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eOperating room adoption depends on surgeon preference and hospital approval.\u003c\/li\u003e\n\u003cli\u003eCapital equipment often needs budget approval before routine use starts.\u003c\/li\u003e\n\u003cli\u003eDigital tools matter when they fit training, planning, and workflow steps.\u003c\/li\u003e\n\u003cli\u003eService and support are part of the channel, not just the product sale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eU.S. and international launches\u003c\/strong\u003e are staged market by market. In the U.S., launch timing depends on regulatory approval, payer coverage, and provider adoption. Outside the U.S., the same product can face separate pricing reviews, reimbursement rules, and tender systems, so launch timing is often uneven across countries. For devices, common U.S. regulatory routes include \u003cstrong\u003e510(k)\u003c\/strong\u003e, \u003cstrong\u003ePMA\u003c\/strong\u003e, and \u003cstrong\u003eDe Novo\u003c\/strong\u003e. For medicines, common routes include \u003cstrong\u003eIND\u003c\/strong\u003e, \u003cstrong\u003eNDA\u003c\/strong\u003e, and \u003cstrong\u003eBLA\u003c\/strong\u003e. These pathway codes matter because they determine how fast a product can move from approval to commercial use. They also determine how much evidence a company must show before a launch can scale.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eU.S. launches often create the first commercial base for a product.\u003c\/li\u003e\n\u003cli\u003eInternational launches follow separate country approvals and reimbursement rules.\u003c\/li\u003e\n\u003cli\u003eDevices can move through \u003cstrong\u003e510(k)\u003c\/strong\u003e, \u003cstrong\u003ePMA\u003c\/strong\u003e, or \u003cstrong\u003eDe Novo\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMedicines can move through \u003cstrong\u003eIND\u003c\/strong\u003e, \u003cstrong\u003eNDA\u003c\/strong\u003e, or \u003cstrong\u003eBLA\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical and regulatory pathways\u003c\/strong\u003e are a channel because they control when a product can reach buyers. Clinical development usually moves through \u003cstrong\u003ePhase 1\u003c\/strong\u003e, \u003cstrong\u003ePhase 2\u003c\/strong\u003e, \u003cstrong\u003ePhase 3\u003c\/strong\u003e, and sometimes \u003cstrong\u003ePhase 4\u003c\/strong\u003e, with evidence building from safety to efficacy to real-world use. For a company like Johnson \u0026amp; Johnson, these stages shape both medicine and device launches, because a product cannot scale commercially until the evidence package and regulatory filing are complete. The channel effect is simple: better data lowers launch risk, improves payer confidence, and supports wider hospital and specialist adoption. Without those steps, even a strong product stays blocked before it reaches procurement systems or prescribers.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePathway\u003c\/th\u003e\n\u003cth\u003eNumeric or coded stage\u003c\/th\u003e\n\u003cth\u003eChannel role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical development\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePhase 1\u003c\/strong\u003e, \u003cstrong\u003ePhase 2\u003c\/strong\u003e, \u003cstrong\u003ePhase 3\u003c\/strong\u003e, \u003cstrong\u003ePhase 4\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBuilds evidence for safety, efficacy, and real-world use.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug approval\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eIND\u003c\/strong\u003e, \u003cstrong\u003eNDA\u003c\/strong\u003e, \u003cstrong\u003eBLA\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eControls when medicines can launch.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice approval\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e510(k)\u003c\/strong\u003e, \u003cstrong\u003ePMA\u003c\/strong\u003e, \u003cstrong\u003eDe Novo\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eControls when MedTech products can launch.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson reported \u003cstrong\u003e$88.8B\u003c\/strong\u003e in 2024 net sales, with \u003cstrong\u003e$57.1B\u003c\/strong\u003e from Innovative Medicine and \u003cstrong\u003e$31.7B\u003c\/strong\u003e from MedTech. Its customer segments split between specialty prescribers, procedure-based providers, and reimbursement decision makers.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer segment\u003c\/td\u003e\n\u003ctd\u003eReal-life numeric anchor\u003c\/td\u003e\n\u003ctd\u003ePrimary buying unit\u003c\/td\u003e\n\u003ctd\u003eRevenue link\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncologists and cancer centers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e new U.S. cancer cases in 2024; \u003cstrong\u003e611,720\u003c\/strong\u003e U.S. cancer deaths in 2024\u003c\/td\u003e\n \u003ctd\u003eSpecialty oncology clinics, hospital cancer centers, infusion sites\u003c\/td\u003e\n \u003ctd\u003eInnovative Medicine \u003cstrong\u003e$57.1B\u003c\/strong\u003e in 2024\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunology, dermatology, and rheumatology patients\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e7.5 million\u003c\/strong\u003e U.S. adults with psoriasis; \u003cstrong\u003e1.5 million\u003c\/strong\u003e U.S. adults with rheumatoid arthritis\u003c\/td\u003e\n \u003ctd\u003eSpecialists, specialty pharmacies, patients with chronic therapy needs\u003c\/td\u003e\n \u003ctd\u003eRecurring specialty prescriptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and ambulatory surgery centers\u003c\/td\u003e\n \u003ctd\u003eMedTech \u003cstrong\u003e$31.7B\u003c\/strong\u003e in 2024; Shockwave Medical acquisition \u003cstrong\u003e$13.1B\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eOperating rooms, inpatient units, outpatient surgery centers\u003c\/td\u003e\n \u003ctd\u003eProcedure equipment, implants, and surgical tools\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular and electrophysiology providers\u003c\/td\u003e\n \u003ctd\u003eShockwave Medical acquisition \u003cstrong\u003e$13.1B\u003c\/strong\u003e; MedTech \u003cstrong\u003e$31.7B\u003c\/strong\u003e in 2024\u003c\/td\u003e\n \u003ctd\u003eCath labs, electrophysiology labs, structural heart teams\u003c\/td\u003e\n \u003ctd\u003eCatheter-based and procedure-based sales\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers and health systems\u003c\/td\u003e\n\u003ctd\u003eU.S. national health expenditures \u003cstrong\u003e$4.9T\u003c\/strong\u003e in 2023; Johnson \u0026amp; Johnson net sales \u003cstrong\u003e$88.8B\u003c\/strong\u003e in 2024\u003c\/td\u003e\n \u003ctd\u003eCommercial insurers, Medicare, Medicaid, integrated delivery systems\u003c\/td\u003e\n \u003ctd\u003eCoverage, formulary access, prior authorization, contracts\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncologists and cancer centers\u003c\/strong\u003e are a core customer segment because \u003cstrong\u003e2,001,140\u003c\/strong\u003e new cancer cases were expected in the U.S. in 2024 and \u003cstrong\u003e611,720\u003c\/strong\u003e cancer deaths were expected in the same year. That scale keeps oncology as a high-volume specialty market inside Johnson \u0026amp; Johnson's \u003cstrong\u003e$57.1B\u003c\/strong\u003e Innovative Medicine business. The buying unit is not the patient alone; it is the oncologist, the tumor board, the cancer center pharmacy, and the infusion site. These customers matter because they control drug selection, sequencing, and continuation across multiple treatment cycles.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e new U.S. cancer cases in 2024\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e611,720\u003c\/strong\u003e U.S. cancer deaths in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImmunology, dermatology, and rheumatology patients\u003c\/strong\u003e represent chronic specialty demand. In the U.S., psoriasis affects \u003cstrong\u003e7.5 million\u003c\/strong\u003e adults and rheumatoid arthritis affects \u003cstrong\u003e1.5 million\u003c\/strong\u003e adults. These segments are important because treatment often runs for months or years, which supports recurring prescription volume rather than one-time sales. The practical customer set includes specialists, specialty pharmacies, and payers that approve long-term therapy. For academic work, this segment shows how Johnson \u0026amp; Johnson depends on chronic disease management, adherence, and access rules instead of only acute care demand.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e7.5 million\u003c\/strong\u003e U.S. adults with psoriasis\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e1.5 million\u003c\/strong\u003e U.S. adults with rheumatoid arthritis\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals and ambulatory surgery centers\u003c\/strong\u003e are central MedTech customers. Johnson \u0026amp; Johnson reported \u003cstrong\u003e$31.7B\u003c\/strong\u003e in MedTech sales in 2024, which makes procedure-based settings a major revenue driver. These customers buy across inpatient surgery, outpatient surgery, and hospital-based procedural care. The segment matters because purchasing is tied to procedure volume, capital budgets, and supply contracts. Johnson \u0026amp; Johnson also paid \u003cstrong\u003e$13.1B\u003c\/strong\u003e for Shockwave Medical in 2024, showing how important cardiovascular and interventional hospital workflows are to the company's customer mix.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMedTech 2024 sales: \u003cstrong\u003e$31.7B\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eShockwave Medical acquisition: \u003cstrong\u003e$13.1B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiovascular and electrophysiology providers\u003c\/strong\u003e are procedure specialists inside hospitals, cath labs, and electrophysiology labs. Their importance sits inside the same \u003cstrong\u003e$31.7B\u003c\/strong\u003e MedTech base and the \u003cstrong\u003e$13.1B\u003c\/strong\u003e Shockwave Medical acquisition. This customer segment buys when a device improves procedural performance, clinical outcomes, or workflow efficiency. The segment is valuable because adoption depends on physician preference, lab standards, and reimbursement, not on patient self-selection. For Johnson \u0026amp; Johnson, this makes cardiovascular providers one of the most commercially sensitive customer groups in MedTech.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayers and health systems\u003c\/strong\u003e shape access across both drug and device businesses. U.S. national health expenditures reached \u003cstrong\u003e$4.9T\u003c\/strong\u003e in 2023, and Johnson \u0026amp; Johnson's 2024 net sales were \u003cstrong\u003e$88.8B\u003c\/strong\u003e, so reimbursement decisions affect a large spending base. Payers decide formulary placement, prior authorization, step therapy, and coverage terms. Health systems decide standard-of-care pathways, preferred vendors, and procurement contracts. This segment matters because even strong clinical data does not translate into sales without coverage and budget approval.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eU.S. national health expenditures in 2023: \u003cstrong\u003e$4.9T\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eJohnson \u0026amp; Johnson 2024 net sales: \u003cstrong\u003e$88.8B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$17.2bn\u003c\/strong\u003e of R\u0026amp;D, \u003cstrong\u003e$22.6bn\u003c\/strong\u003e of SG\u0026amp;A, \u003cstrong\u003e$13.1bn\u003c\/strong\u003e for Shockwave Medical, \u003cstrong\u003e$16.6bn\u003c\/strong\u003e for Abiomed, \u003cstrong\u003e$8.9bn\u003c\/strong\u003e for talc settlement exposure, and \u003cstrong\u003e$2bn\u003c\/strong\u003e for manufacturing localization are the largest numeric cost markers in the latest public figures used here.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost bucket\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003ctd\u003eShare of \u003cstrong\u003e$88.8bn\u003c\/strong\u003e sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D and clinical trials\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, marketing and administrative expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.6bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShockwave Medical acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.1bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbiomed acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.6bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalc settlement proposal\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.9bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing site investment in Wilson, North Carolina\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eannounced\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D plus SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$39.8bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition spending, Shockwave Medical plus Abiomed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.7bn\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022-2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D and clinical trials:\u003c\/strong\u003e \u003cstrong\u003e$17.2bn\u003c\/strong\u003e; \u003cstrong\u003e19.4%\u003c\/strong\u003e of \u003cstrong\u003e$88.8bn\u003c\/strong\u003e sales.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$17.2bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e19.4%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$39.8bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e44.8%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquisitions and integration costs:\u003c\/strong\u003e \u003cstrong\u003e$13.1bn\u003c\/strong\u003e and \u003cstrong\u003e$16.6bn\u003c\/strong\u003e; combined \u003cstrong\u003e$29.7bn\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$13.1bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$16.6bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$29.7bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e33.4%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing capex and localization:\u003c\/strong\u003e \u003cstrong\u003e$2bn\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$2bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2.3%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLitigation and settlement expenses:\u003c\/strong\u003e \u003cstrong\u003e$8.9bn\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$8.9bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e10.0%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSG\u0026amp;A and restructuring costs:\u003c\/strong\u003e \u003cstrong\u003e$22.6bn\u003c\/strong\u003e; combined with R\u0026amp;D, \u003cstrong\u003e$39.8bn\u003c\/strong\u003e; \u003cstrong\u003e44.8%\u003c\/strong\u003e of \u003cstrong\u003e$88.8bn\u003c\/strong\u003e sales.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$22.6bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$39.8bn\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e44.8%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRestructuring costs:\u003c\/strong\u003e n\/a in the figures used here.\u003c\/p\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$88.8B\u003c\/strong\u003e in 2024 net sales came from \u003cstrong\u003e$57.4B\u003c\/strong\u003e Innovative Medicine, \u003cstrong\u003e$31.4B\u003c\/strong\u003e MedTech, \u003cstrong\u003e$45.9B\u003c\/strong\u003e U.S. sales, and \u003cstrong\u003e$42.9B\u003c\/strong\u003e international sales.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue stream\u003c\/td\u003e\n\u003ctd\u003e2024 amount\u003c\/td\u003e\n\u003ctd\u003eShare of total sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInnovative Medicine\u003c\/td\u003e\n\u003ctd\u003e$57.4B\u003c\/td\u003e\n\u003ctd\u003e64.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech\u003c\/td\u003e\n\u003ctd\u003e$31.4B\u003c\/td\u003e\n\u003ctd\u003e35.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003e$45.9B\u003c\/td\u003e\n\u003ctd\u003e51.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003e$42.9B\u003c\/td\u003e\n\u003ctd\u003e48.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative Medicine product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDarzalex: \u003cstrong\u003e$11.7B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eStelara: \u003cstrong\u003e$10.4B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTremfya: \u003cstrong\u003e$3.8B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCarvykti: \u003cstrong\u003e$963M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSpravato: \u003cstrong\u003e$941M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDarzalex + Stelara: \u003cstrong\u003e$22.1B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDarzalex + Stelara as a share of Innovative Medicine: \u003cstrong\u003e38.5%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDarzalex + Stelara as a share of total company sales: \u003cstrong\u003e24.9%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMedTech device and platform sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech segment sales\u003c\/td\u003e\n\u003ctd\u003e$31.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbiomed acquisition value\u003c\/td\u003e\n\u003ctd\u003e$16.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShockwave acquisition value\u003c\/td\u003e\n\u003ctd\u003e$13.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbiomed + Shockwave\u003c\/td\u003e\n\u003ctd\u003e$29.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eNew-launch portfolio growth\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCarvykti: \u003cstrong\u003e$963M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSpravato: \u003cstrong\u003e$941M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCarvykti + Spravato: \u003cstrong\u003e$1.904B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCarvykti + Spravato as a share of Innovative Medicine: \u003cstrong\u003e3.3%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eU.S. and international sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003e$45.9B\u003c\/td\u003e\n\u003ctd\u003e51.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003e$42.9B\u003c\/td\u003e\n\u003ctd\u003e48.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal\u003c\/td\u003e\n\u003ctd\u003e$88.8B\u003c\/td\u003e\n\u003ctd\u003e100.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquired franchise contributions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAbiomed: \u003cstrong\u003e$16.6B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eShockwave: \u003cstrong\u003e$13.1B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAbiomed + Shockwave: \u003cstrong\u003e$29.7B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMedTech segment sales: \u003cstrong\u003e$31.4B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601607618709,"sku":"jnj-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/jnj-business-model-canvas.png?v=1740187357","url":"https:\/\/dcf-model.com\/es\/products\/jnj-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}